The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
President Trump also said he is "not looking for a partial deal" with Beijing, moving away from his suggestion last week that he would consider an "interim deal."Politicsread more
Progress on trade talks will determine how far market will move above new highs.Trader Talk with Bob Pisaniread more
"Sure, the trade war's taking its toll on business ... it's just not taking its toll where it was supposed to," Jim Cramer says.Mad Money with Jim Cramerread more
Joe Biden called on President Donald Trump Friday to release the transcript of a call with a foreign leader that is the subject of a whistleblower complaint. Biden described...Politicsread more
Indianapolis drug giant Eli Lilly raised list prices of nine of its medicines last week between 6 and 10 percent, according to data obtained by CNBC.
The increases, taken on May 2, were for drugs including the blood thinner Effient (9.9 percent), the psoriasis drug
The increases fit a pattern at Lilly and many other drugmakers of single-digit percentage hikes once or twice a year, despite political pressure and intense scrutiny of the practices. Lilly has come under fire for the price of its insulin
Lilly confirmed the price increases in an emailed statement to CNBC, and noted the list prices "do not reflect the significant discounts and rebates that we provide to ensure patients have adequate access to our medicines."
"The net price increase that Lilly recognizes is significantly less," spokesman Mark Taylor wrote. "In fact, in 2016, the average discount to list price on our U.S. portfolio rose to 50 percent and net prices rose just 2.4 percent in the U.S."
Rebates on list prices of medicines are negotiated by pharmacy benefits managers. Drugmakers argue few patients are exposed to the list prices of medicines because of these discounts and rebates.
One of the largest pharmacy benefits managers, Express Scripts, announced this week a program to offer lower drug prices to patients without health insurance or who have high-deductible plans that make out-of-pocket costs for medicines untenable.
Lilly's chief executive, Dave Ricks, appeared on CBS This Morning with Express Scripts Chief Tim Wentworth to praise the program, called Inside Rx.
"We wake up every day trying to invent new medicines and get them to people who are sick," Ricks said. "This initiative… is
Lilly's product Humalog is included in the program, Ricks said. Outside of programs like this one, patients without insurance generally don't get access to the
"When people go to the pharmacy counter and have that sticker shock, often they do walk away," Ricks said. "This, maybe, can bridge some people to fill their prescription, control their diabetes a little better. I think everyone's better off in that system."
Lilly took list price increases on those medicines of between 18 and 24 percent in 2014, 17 and 32 percent in 2015, and 7.5 and 21 percent in 2016, according to analysts at Bernstein Research, who confirmed the recent 2017 increases as well.
When pricing its products, Lilly takes into account "the value they bring to patients and the healthcare system, as well as current marketplace conditions and the need to fund the development of the next generation of innovative medicines," Taylor said.
Amid heightened political scrutiny of drug prices, many manufacturers have pledged to curb increases. Allergan said it plans to keep price increases to less than 10 percent a year, sticking to 9.5 percent for a number of its drugs in 2017.
The pledges come as President Donald Trump has maintained a focus on the issue, saying the pharmaceutical industry is "getting away with murder" when it comes to its prices.